Author: Mathilde Gasnier

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian Patent Office (IP Australia) has granted Australian Patent No. 2022370513, entitled “Compositions Comprising Ciprofloxacin and Celecoxib,” representing another strategic step in the continued expansion of the Company’s global intellectual property protection for PrimeC.Read More

Read More

In today’s rapidly evolving global workforce, innovative companies are exploring compensation models that incorporate cryptocurrency, such as Bitcoin, Ethereum, and stablecoins like USDC, EURC, or emerging euro-pegged options such as Fia, to attract top talent, streamline operations, and stay competitive, often supplementing traditional fiat-only payment systems (i.e., government-issued currency such as the U.S. dollar, euro, or pound sterling). While crypto payroll offers efficiencies for distributed teams, it also raises significant tax, regulatory, and operational risks, particularly when implementing globally.Read More

Read More